| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | 0.079 | 0.03 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.073 | 0.03 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.079 | 0.03 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | 0.083 | 0.03 |
| mRNA | PF-184 | CTRPv2 | pan-cancer | AAC | 0.078 | 0.03 |
| mRNA | AZD4547 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.03 |
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | 0.07 | 0.03 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.12 | 0.03 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | 0.074 | 0.03 |
| mRNA | DMOG | GDSC1000 | pan-cancer | AAC | -0.074 | 0.04 |